Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients

References

• Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin. 2019;37(1):83–94.
   PubMed Web of Science ®Google Scholar
• O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253–261.
   PubMed Web of Science ®Google Scholar
• Madan V, Lear JT, Szeimies RM. Nonmelanoma skin cancer. Lancet. 2010;375(9715):673–685.
   PubMed Web of Science ®Google Scholar
• O'Reilly Zwald F, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–279.
   PubMed Web of Science ®Google Scholar
• Guminski A, Stein B. Immunotherapy and other systemic therapies for cutaneous SCC. Oral Oncol. 2019;99:104459.
   PubMed Web of Science ®Google Scholar
• Lai HC, Lin JF, Hwang TIS, et al. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? IJMS. 2019;20(9):2194.
   Google Scholar
• Hanania HL, Lewis DJ. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma. Expert Rev Anticancer Ther. 2022;22(2):237–238.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Safa H, Abudayyeh A. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7:106.
   PubMed Web of Science ®Google Scholar
• DeLeon TT, Salomao MA, Aqel BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo clinic experience. J Gastrointest Oncol. 2018;9(6):1054–1062.
   PubMed Web of Science ®Google Scholar
• Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. The Oncologist. 2020;25(6):505–514.
   PubMed Web of Science ®Google Scholar
• Fisher J, Zeitouni N, Fan W, et al. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2020;82(6):1490–1500.
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–351.
   PubMed Web of Science ®Google Scholar
• Portuguese AJ, Tykodi SS, Blosser CD, et al. Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review. J Natl Compr Canc Netw. 2022;20(4):406–416.e11.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist. 2021;26(2):133–138.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Ow TJ. Safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp. Curr Oncol. 2021;28(1):574–580. Published 2021 Jan 19.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Abdalla B, Mendenhall MA, et al. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report. BMC Nephrol. 2018;19(1):210–Published 2018 Aug 20.
   PubMedGoogle Scholar
• Lee BT, Horwich BH, Chopra S, et al. Checkpoint inhibitor-induced rejection of a liver allograft: a combination of acute T cell-mediated and antibody-mediated rejection. Liver Transpl. 2019;25(12):1845–1848.
   PubMed Web of Science ®Google Scholar
• Brumfiel CM, Patel MH, Aqel B, et al. Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma. JAAD Case Rep. 2021;14:78–81.
   PubMedGoogle Scholar
• Venkatachalam K, Malone AF, Heady B, et al. Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients. Transplantation. 2020;104(5):1041–1047.
   PubMed Web of Science ®Google Scholar
• Ali SA, Arman HE, Patel AA, et al. Successful administration of cemiplimab to a patient with advanced cutaneous squamous cell carcinoma after renal transplantation. J Clin Oncol Oncol Pract. 2020;16(3):137–138.
   PubMedGoogle Scholar
• Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist. 2020;25(6):505–514.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Bagnasco SM, Moore J, Jr, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374(9):896–898.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Naqvi FF, Loss MJ, et al. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Am J Transplant. 2020;20(8):2264–2268.
   PubMed Web of Science ®Google Scholar
• Daud A, Mehra MR, Siu A, et al. Immune checkpoint inhibitors in heart or lung transplantation: Early results from a registry initiative. J Heart Lung Transplant. 2020;39(6):604–606.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Kumar M, Yang S, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother. 2017;66(1):45–50.
   PubMed Web of Science ®Google Scholar
• Kittai AS, Oldham H, Cetnar J, et al. Immune checkpoint inhibitors in organ transplant patients. J Immunother. 2017;40(7):277–281.
   PubMed Web of Science ®Google Scholar
• Geidel G, Rünger A, Schneider SW, et al. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report. J Eur Acad Dermatol Venereol. 2022;36(Suppl 1):49–52.
   PubMedGoogle Scholar
• O'Connell KA, Schmults CD. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy. J Eur Acad Dermatol Venereol. 2022;36(Suppl 1):45–48.
   PubMedGoogle Scholar
• Gambichler T, Hessam S, Lüttringhaus T, et al. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus [published online ahead of print, 2021 nov 12]. Clin Exp Dermatol. 2021;47(3):608–609.
   PubMed Web of Science ®Google Scholar
• Orte Cano C, Van Meerhaeghe T, Tannous J, et al. Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab. J Eur Acad Dermatol Venereol. 2022;36(Suppl 1):53–58.
   PubMed Web of Science ®Google Scholar
• Su T, Racz E, Wiegman MJ, et al. Sustained complete response of metastatic cutaneous squamous cell carcinoma by immune checkpoint inhibition in a renal transplant patient: a case report [published online ahead of print, 2022 may 24]. Acad Dermatol Venereol. 2022;36(9):e735–e737.
   PubMed Web of Science ®Google Scholar
• Bastos S, Masmoudi W, Pinard C, et al. Efficacy of nivolumab in the treatment of metastatic cutaneous squamous cell carcinoma in a kidney-transplant patient with a history of allograft rejection. Ann Dermatol Venereol. 2022. DOI:10.1016/j.annder.2022.01.003
   PubMed Web of Science ®Google Scholar
• Sadaat M, Jang S. Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy. J Oncol Pract. 2018;14(3):198–199.
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Mulvaney PM, Murakami N, et al. Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy. Cancer Immunol Immunother. 2020;69(9):1937–1941.
   PubMed Web of Science ®Google Scholar
• Hermida-Lama E, Rodriguez D, Cuadrado E, et al. Accelerated cellular rejection with prominent interstitial hemorrhage following cemiplimab treatment: how can we approach a renal transplant recipient under anti-PD1 therapy? Journal of Onco-Nephrology. 2021;5(2):145–149.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and Meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Murakami N, Mulvaney P, Danesh M, Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100(1):196–205.
   PubMed Web of Science ®Google Scholar
• Ducroux E, Martin C, Bouwes Bavinck JN, et al. Risk of aggressive skin cancers after kidney retransplantation in patients with previous posttransplant cutaneous squamous cell carcinomas: a retrospective study of 53 cases. Transplantation. 2017;101(4):e133–e141.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–1911.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Karia PS, Azzi JR, Heher EC, et al. Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer. JAMA Dermatol. 2016;152(5):533–540.
   PubMed Web of Science ®Google Scholar
• Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and Meta-analysis of individual patient data [published correction appears in BMJ. 2014;349:g7543]. BMJ. 2014;349:g6679.
   PubMed Web of Science ®Google Scholar
• Bossi P, Lorini L. Treatment of cutaneous squamous cell carcinoma with immune checkpoint inhibitors in special populations. Dermatol Pract Concept. 2021;11(Suppl 2):e2021170S.
   PubMedGoogle Scholar
• Lakhani L, Alasfar S, Bhalla A, et al. Utility of serial donor-derived cell-free DNA measurements for detecting allograft rejection in a kidney transplant recipient after PD-1 checkpoint inhibitor administration. Transplant Direct. 2021;7(2):e656.
   PubMed Web of Science ®Google Scholar